Novo Nordisk Executive Sees Inhaled Insulin as Niche Product

Pfizer Inc.’s (PFE) recent decision to stop selling the first inhaled form of insulin cast a shadow over the future of such diabetes treatments, which rival companies have been developing.
CNN Money